FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer

Saima Sharif; Michael J O'Connell; Greg Yothers; Samia Lopa; Norman Wolmark

doi:10.1080/07357900802132550

Back

FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer

Journal article

Peer reviewed

FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer

Saima Sharif, Michael J O'Connell, Greg Yothers, Samia Lopa and Norman Wolmark

Cancer investigation, Vol.26(9), pp.956-963

11/2008

DOI: 10.1080/07357900802132550

PMCID: PMC2588473

PMID: 18798075

Files and links (1)

url

http://doi.org/10.1080/07357900802132550View

Open Access

Abstract

The MOSAIC trial showed that the use of adjuvant oxaliplatin and an infusional regimen of 5-FU/LV in the treatment of stage II/III colon cancer improved disease-free survival (DFS). The NSABP's C-07 trial evaluated the addition of oxaliplatin to a weekly Roswell Park regimen of bolus 5-FU/LV and found a similar improvement in DFS. The benefit of oxaliplatin appears to be independent of the 5-FU/LV regimen used. This paper reviews the efficacy and toxicities of these two regimens and is meant to serve as a guide for clinical practice.

Colonic Neoplasms - drug therapy

Humans

Middle Aged

Antineoplastic Combined Chemotherapy Protocols - adverse effects

Male

Treatment Outcome

Randomized Controlled Trials as Topic

Adjuvants, Immunologic - adverse effects

Disease-Free Survival

Fluorouracil - therapeutic use

Leucovorin - adverse effects

Fluorouracil - adverse effects

Antineoplastic Combined Chemotherapy Protocols - therapeutic use

Colonic Neoplasms - pathology

Female

Leucovorin - therapeutic use

Neoplasm Staging

Adjuvants, Immunologic - therapeutic use

Organoplatinum Compounds - therapeutic use

Organoplatinum Compounds - adverse effects

Practice Guidelines as Topic

Details

Title: Subtitle: FOLFOX and FLOX regimens for the adjuvant treatment of resected stage II and III colon cancer
Creators: Saima Sharif - National Surgical Adjuvant Breast and Bowel Project Operations Office, Pittsburgh, Pennsylvania, USA. saima.sharif@nsabp.org
Michael J O'Connell
Greg Yothers
Samia Lopa
Norman Wolmark
Resource Type: Journal article
Publication Details: Cancer investigation, Vol.26(9), pp.956-963
DOI: 10.1080/07357900802132550
PMID: 18798075
PMCID: PMC2588473
NLM abbreviation: Cancer Invest
ISSN: 0735-7907
eISSN: 1532-4192
Grant note: U10 CA012027 / NCI NIH HHS U10 CA037377-22 / NCI NIH HHS U10 CA012027-34 / NCI NIH HHS U10 CA012027-32S1 / NCI NIH HHS U10 CA012027-37S1 / NCI NIH HHS U10 CA012027-38 / NCI NIH HHS U10 CA069974-11 / NCI NIH HHS U10 CA037377-17 / NCI NIH HHS U10 CA069651-13 / NCI NIH HHS U10 CA012027-33 / NCI NIH HHS U10 CA037377-21 / NCI NIH HHS U10 CA069651-12 / NCI NIH HHS U10 CA012027-33S2 / NCI NIH HHS U10 CA069974-10 / NCI NIH HHS U10 CA012027-37 / NCI NIH HHS U10CA-69651 / NCI NIH HHS U10 CA037377-16 / NCI NIH HHS U10 CA037377 / NCI NIH HHS U10CA-69974 / NCI NIH HHS U10 CA012027-30 / NCI NIH HHS U10 CA012027-32 / NCI NIH HHS U10 CA037377-20 / NCI NIH HHS U10 CA037377-15 / NCI NIH HHS U10 CA069651-11 / NCI NIH HHS U10 CA012027-36 / NCI NIH HHS U10CA-12027 / NCI NIH HHS U10 CA037377-19 / NCI NIH HHS U10 CA069651 / NCI NIH HHS U10 CA069974-11S2 / NCI NIH HHS U10 CA012027-31S1 / NCI NIH HHS U10 CA012027-31 / NCI NIH HHS U10CA-37377 / NCI NIH HHS U10 CA069974 / NCI NIH HHS U10 CA069651-15 / NCI NIH HHS U10 CA012027-35 / NCI NIH HHS U10 CA069974-12 / NCI NIH HHS U10 CA037377-18 / NCI NIH HHS U10 CA069651-14 / NCI NIH HHS U10 CA012027-33S1 / NCI NIH HHS
Language: English
Date published: 11/2008
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
Record Identifier: 9984094525102771

Metrics

29 Record Views

59 Times Cited - Web of Science